Charles M Rudin Selected Research

Small Cell Lung Carcinoma (Small Cell Lung Cancer)

1/2022	Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
1/2022	Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.
1/2022	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.
12/2021	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.
11/2021	MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer.
1/2021	Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
12/2020	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
1/2020	Targeted Therapies and Biomarkers in Small Cell Lung Cancer.
1/2020	SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
1/2020	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles M Rudin Research Topics

Disease

129	Neoplasms (Cancer) 01/2022 - 01/2002
59	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2009
46	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 03/2004
41	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2002
20	Adenocarcinoma of Lung 01/2022 - 04/2013
12	Disease Progression 01/2022 - 02/2003
10	Neoplasm Metastasis (Metastasis) 01/2020 - 11/2013
9	Carcinogenesis 01/2021 - 11/2005
8	Medulloblastoma 04/2015 - 09/2009
7	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2014
7	Basal Cell Carcinoma (Rodent Ulcer) 06/2015 - 09/2009
6	Fatigue 01/2020 - 02/2006
6	Thrombocytopenia (Thrombopenia) 10/2018 - 11/2004
5	Hypersensitivity (Allergy) 01/2021 - 11/2004
5	Adenocarcinoma 01/2020 - 01/2015
5	Neutropenia 10/2018 - 04/2002
4	Carcinoma (Carcinomatosis) 01/2020 - 01/2016
4	Nausea 01/2020 - 03/2011
4	Brain Neoplasms (Brain Tumor) 01/2020 - 03/2006
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 08/2015
3	Pleural Effusion (Pleural Effusions) 12/2021 - 02/2003
3	Diarrhea 01/2020 - 03/2008
2	Glioma (Gliomas) 01/2022 - 01/2021
2	Small Cell Carcinoma 01/2021 - 01/2019
2	Exanthema (Rash) 01/2020 - 03/2008
2	Vomiting 01/2020 - 05/2015
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 11/2009
2	Carcinoid Tumor (Carcinoid) 01/2019 - 03/2014

Drug/Important Bio-Agent (IBA)

23	Pharmaceutical PreparationsIBA 01/2022 - 02/2006
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2006
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2011
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2013
10	Biological ProductsIBA 01/2022 - 02/2003
10	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2008
10	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 03/2004
10	HhAntag691IBA 08/2016 - 09/2009
9	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 05/2002
9	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
9	LigandsIBA 01/2022 - 01/2012
8	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2011
7	Phosphotransferases (Kinase)IBA 01/2021 - 03/2008
7	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 10/2006
7	PlatinumIBA 01/2021 - 01/2005
7	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 10/2002
7	ErbB Receptors (EGF Receptor)IBA 12/2019 - 03/2008
6	Transcription Factors (Transcription Factor)IBA 01/2022 - 09/2017
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 03/2008
6	Docetaxel (Taxotere)FDA Link 10/2015 - 05/2002
6	Antisense OligonucleotidesIBA 02/2008 - 04/2002
5	Circulating Tumor DNAIBA 01/2022 - 01/2017
5	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 04/2004
5	Cell-Free Nucleic AcidsIBA 01/2022 - 11/2019
5	Peptides (Polypeptides)IBA 01/2020 - 03/2011
4	ChromatinIBA 01/2022 - 11/2009
4	Messenger RNA (mRNA)IBA 01/2022 - 11/2009
4	CrizotinibIBA 01/2020 - 06/2011
4	Gemcitabine FDA Link 01/2020 - 05/2002
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 05/2013
4	rovalpituzumab tesirineIBA 12/2019 - 08/2015
4	Itraconazole (Sporanox)FDA LinkGeneric 05/2013 - 10/2011
3	pembrolizumabIBA 01/2022 - 01/2020
3	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2019
3	Silicon Dioxide (Silica)FDA LinkGeneric 01/2022 - 01/2020
3	MethyltransferasesIBA 01/2022 - 05/2013
3	osimertinibIBA 10/2021 - 01/2018
3	EnzymesIBA 01/2021 - 01/2017
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018 - 01/2017
3	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 03/2006
3	CarcinogensIBA 09/2017 - 09/2009
3	Monoclonal AntibodiesIBA 03/2017 - 02/2009
3	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2017 - 06/2013
3	Azacitidine (5 Azacytidine)FDA Link 01/2015 - 12/2011
3	navitoclaxIBA 05/2014 - 03/2011
3	ABT-737IBA 05/2014 - 04/2008
3	SmokeIBA 09/2012 - 09/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2009 - 02/2003
2	InterferonsIBA 01/2022 - 01/2022
2	trametinibIBA 01/2022 - 01/2016
2	Retroelements (Retrotransposon)IBA 01/2022 - 03/2011
2	Mitogen-Activated Protein KinasesIBA 11/2021 - 12/2018
2	Aurora Kinase BIBA 01/2021 - 10/2014
2	pevonedistatIBA 01/2021 - 01/2017
2	durvalumabIBA 01/2020 - 01/2020
2	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
2	Lipase (Acid Lipase)FDA Link 01/2020 - 01/2017
2	ORALIT (ORS)IBA 12/2019 - 09/2012
2	human ERBB2 proteinIBA 12/2019 - 01/2018
2	CytokinesIBA 11/2019 - 02/2003
2	talazoparibIBA 10/2019 - 10/2018
2	B7-H1 AntigenIBA 01/2018 - 03/2017
2	NivolumabIBA 01/2018 - 10/2015

Therapy/Procedure

92	Therapeutics 01/2022 - 01/2002
22	Drug Therapy (Chemotherapy) 01/2022 - 02/2003
12	Immunotherapy 11/2021 - 01/2015
6	Radiotherapy 01/2021 - 10/2002
3	Radioimmunotherapy 01/2022 - 01/2021
2	Chemoradiotherapy 01/2022 - 01/2008
2	Aftercare (After-Treatment) 01/2020 - 02/2011
2	Precision Medicine 12/2017 - 01/2017
2	Cranial Irradiation 10/2017 - 10/2017